|
|
|
| Expression and significance of IL-17 and IL-38 in triple negative breast cancer |
| WU Jiang1 YE Biaofei2 MENG Qingjie3 FAN Jing1 LI Nanlin1 LING Rui1 |
1.Department of Thyroid Breast and Vascular Surgery, Xijing Hospital, Shaanxi Province, Xi′an 710032, China;
2.Department of Oncology, Tangdu Hospital the Fourth Military Medical University, Shaanxi Province, Xi′an 710038, China;
3.Department of Thyroid and Breast Surgery, the Affiliated Hospital of Northwest University Xi′an No.3 Hospital, Shaanxi Province, Xi′an 710018, China |
|
|
|
Abstract Objective To detect the expression of IL-17 and IL-38 in triple negative breast cancer (TNBC) patients, and to explore their possible role in the pathogenesis of breast cancer. Methods From November 2017 to March 2019, 71 cases with breast cancer admitted to Xijing Hospital (“our hospital”for short) were selected as study subjects, including 36 cases in the TNBC group and 35 cases in the ductal carcinoma in situ (DCIS) group, and 33 patients with fibroadenoma who admitted to our hospital at the same time were selected as the control group. The expression of interleukin (IL-17) mRNA and IL-38 mRNA in tissue samples were detected by real-time RT-PCR; and the protein expression of IL-17 and IL-38 were detected by immunohistochemistry. The correlation between IL-17 mRNA expression and IL-38 mRNA expression in the TNBC group was further analyzed. Results The expression IL-17 mRNA in TNBC group and DCIS group were higher than those in control group, and the differences were statistically significant (all P < 0.05). While the expression of IL-38 mRNA in TNBC group and DCIS group were lower than those in control group, and the differences were statistically significant (all P < 0.05). The protein positive expression of IL-17 in TNBC group was higher than that in DCIS group and control group, and the differences were statistically significant (all P < 0.05). While the protein positive expression of IL-38 in TNBC group and DCIS group were lower than those in control group, and the differences were statistically significant (all P < 0.05). The relative expression of IL-17 mRNA and IL-38 mRNA was negatively correlated in TNBC(r = -0.685, P < 0.01). Conclusion The expression of IL-17 is increased and IL-38 is decreased in TNBC. There is a negative correlation between IL-17 mRNA and IL-38 mRNA. They may play an opposite role in the pathogenesis of TNBC.
|
|
|
|
|
|
[1] DeSantis CE，Ma J，Gaudet MM，et al. Breast Cancer Statistics，2019 [J]. CA Cancer J Clin，2019，69（6）：438-451.
[2] Chen W，Zheng R，Baade PD，et al. Cancer statitics in China，2015 [J]. CA Cancer J Clin，2016，66（2）：115-132.
[3] Escórcio-Dourado CS，Martins LM，Simpl cio-Revoredo CM，et al. Bcl-2 antigen expression in luminal A and triple-negative breast cancer [J]. Med Oncol，2017，34（9）：161.
[4] Khosravi-Shahi P，Cabezón-Gutiérrez L，Custodio-Cabello S. Metastatic triple negative breast cancer：Optimizing treatment options，new and emerging targeted therapies [J]. Asia Pac J Clin Oncol，2018，14（1）：32-39.
[5] 王国庆，刘燕，高鸿霞.IL-17A在乳腺浸润性导管癌中表达及对MCF-7细胞增殖转移的作用[J].北华大学学报：自然科学版，2018，19（5）：616-618.
[6] He D，Li H，Yusuf N，et al. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells [J]. J Immunol，2010，184（5）：2281-2288.
[7] 张瑜，金建军，田笑笑.IL-38及其受体IL-36R mRNA在结直肠癌中的表达及意义[J].胃肠病学和肝病学杂志，2018，27（12）：1383-1385.
[8] Takada K，Okamoto T，Tominaga M，et al. Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma：Possible association with PD-L1 expression [J]. PLoS One，2017，12（7）：e0181598.
[9] Mora J，Schlemmer A，Wittig I，et al. Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses [J]. J Mol Cell Biol，2016，8（5）：426-438.
[10] Cserni G，Chmielik E，Cserni B，et al. The new TNM-based staging of breast cancer [J]. Virchows Arch，2018，472（5）：697-703.
[11] Mombelli S，Cochaud S，Merrouche Y，et al. IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells [J]. Sci Rep，2015，5：11874.
[12] 孟庆杰，巫姜，石文龙，等.三阴性乳腺癌IL-17基因Real-time RT-qPCR检测法的建立与应用[J].现代肿瘤医学，2017，25（15）：2357-2361.
[13] Chand P，Garg A，Singla V，et al. Evaluation of Immunohistochemical Profile of Breast Cancer for Prognostics and Therapeutic Use [J]. Niger J Surg，2018，24（2）：100-106.
[14] 邹兴文，杨丽，李伟栋.广州市173335名农村妇女乳腺癌筛查分析[J].中国肿瘤，2018，27（8）：568-572.
[15] 曹明丽，宋丰举.基于分子分型的乳腺癌流行病学新认识[J].中国肿瘤临床，2017，44（9）：449-451.
[16] Austin D，Hamilton N，Elshimalir，et al. Estrogen receptor-beta is a potential target for triple negative breast cancer treatment [J]. Oncotarget，2018，9（74）：33912-33930.
[17] 李必一，王若雨，赵勇.IL-17在肿瘤发生发展中的作用及其临床意义[J].中国医药生物技术，2016，11（1）：64-68.
[18] Huang Q，Duan L，Qian X，et al. IL-17 promotes angiogenic factors IL-6，IL-8，and vegf production via stat1 in lung adenocarcinoma [J]. Sci Rep，2016，6：36551.
[19] Chen WC，Lai YH，Chen HY，et al. Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor [J]. Histopathology，2013，63（2）：225-233.
[20] van de Veerdonk FL，Stoeckman AK，Wu G，et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist [J]. Proc Natl Acad Sci USA，2012，109（8）：3001-3005.
[21] Ye CY，Liu A，Xu MY，et al． Arthroplasty versus Internal Fixation for Displaced Intracapsular Femoral Neck Fracture in the Elderly：Systematic Review and Meta-analysis of Short-and Long-term Effectiveness [J]. Chin Med J（Engl），2016，129（21）：2630-2638.
[22] 肖盼盼，付冰冰，孙雪茜，等.IL-38和IL-17在类风湿关节炎中的表达水平及临床意义[J].湖北民族学院学报：医学版，2019，36（1）：35-37，48.
[23] 张黎，姜姗，刘淼，等.IL-38、IL-22和IL-17与乳腺癌发展的相关性研究[J].现代免疫学，2018，38（3）：237-242. |
|
|
|
